Dr. Qian Yin, from Biomedical Engineering, recently joined the Materials Science & Engineering Graduate Studies Committee this month and is eager to start working with MS&E students.
Research in the Yin lab focuses on employing a biomaterials-centric approach to elucidate the key mechanism for potentiating or diversifying the immune responses, and in parallel, to precisely modulate the immune system and create new immunotherapies against cancer and infectious diseases. The Yin lab leverages cutting-edge technologies in synthetic chemistry, materials science, nanotechnology, systems immunology, and organoid models to advance developments in cancer immunotherapy and anti-viral vaccines. "Our ultimate goal is to translate these new technologies and therapies for clinical applications."
What did you do before your current position?
Before coming to UT, I was an Instructor in the Institute for Immunity, Transplantation and Infection at Stanford University. I also did my postdoc training there, working with Prof. Mark Davis.
What motivated you to become involved in Materials Science Engineering?
I studied polymer chemistry during my undergraduate studies, and then I was really fascinated by applying polymer chemistry to synthesize functional biomaterials for different applications. So I ended up joining the Department of Materials Science and Engineering at UIUC for my graduate studies and delve deeper into the Materials Science and Engineering field.
Describe the most memorable event or experience you’ve encountered in your career?
One successful experiment during the COVID-19 pandemic is the most memorable event recently happening in my career. During the pandemic, we work very hard trying to find a solution for effective vaccines. As a materials scientist, I want to apply materials principles to develop an adjuvant that helps our body develop a broad antibody response against ever-mutating viruses. In fact, I achieve that. I still remember how satisfied I was when I saw mice immunized with my developed vaccine, only one single viral strain from 2019 can elicit potent cross-reactive antibodies against different variants of concern including Delta and Omicron. At that moment, it really makes me feel I am using my expertise to help people and contribute to a better world.
What is your favorite thing to do when you’re not working?
I like cooking with new recipes, decorating the house in a different way, and traveling to different countries.